株式会社Veritas In Silico Logo

株式会社Veritas In Silico

An in silico drug discovery platform creating mRNA-targeting medicines with pharma partners.

130A | T

Overview

Corporate Details

ISIN(s):
JP3155340007
LEI:
Country:
Japan
Address:
品川区西五反田一丁目11番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Veritas In Silico Inc. is a drug discovery platform company specializing in the creation of small molecule and nucleic acid medicines that target messenger RNA (mRNA). The company utilizes its proprietary *in silico* (computational simulation) technologies, combining quantum chemistry calculations with robust high-throughput screening, to design novel therapeutics for previously undruggable targets. Its core business involves establishing joint research and development partnerships with major pharmaceutical companies, earning revenue through milestone payments and future royalties. Veritas In Silico has secured numerous collaborations with leading firms such as Takeda, Shionogi, and Mitsubishi Gas Chemical. The company was listed on the Tokyo Stock Exchange Growth Market in February 2024.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:00
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 177.7 KB
2025-08-14 08:00
Interim Report
確認書
Japanese 8.8 KB
2025-03-28 05:18
Post-Annual General Meeting Information
臨時報告書
Japanese 27.1 KB
2025-03-28 02:47
Regulatory News Service
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-28 02:47
Regulatory News Service
確認書
Japanese 8.8 KB
2025-03-28 02:46
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 3.1 MB
2024-08-14 08:00
Interim Report
確認書
Japanese 8.7 KB
2024-08-14 08:00
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 171.1 KB
2024-05-15 09:55
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-05-15 08:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 146.8 KB
2024-03-15 07:01
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2024-03-15 07:00
Annual Report
有価証券報告書-第8期(2023/01/01-2023/12/31)
Japanese 3.1 MB
2024-02-08 01:05
Major Shareholding Notification
臨時報告書
Japanese 21.1 KB
2024-01-31 07:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-01-23 07:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB

Automate Your Workflow. Get a real-time feed of all 株式会社Veritas In Silico filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 株式会社Veritas In Silico

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 株式会社Veritas In Silico via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

QUINSTREET, INC Logo
AI-driven marketplaces connecting consumers to brands in finance & home services on a pay-per-result basis.
United States of America
QNST
Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978

Talk to a Data Expert

Have a question? We'll get back to you promptly.